InnoCare Pharma Limited
Status: Publicly traded
Direct answer
InnoCare Pharma Limited is publicly traded on HKSE under the ticker 9969.HK.
InnoCare Pharma Limited, a biopharmaceutical enterprise, specializes in the discovery, development, and commercialization of therapeutic agents for oncological and autoimmune disorders. Its lead product, Orelabrutinib, a BTK inhibitor, addresses a wide range of conditions, including various forms of relapsed and/or refractory (r/r) lymphomas (such as chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's...
Can you invest in InnoCare Pharma Limited?
Yes. InnoCare Pharma Limited trades publicly on HKSE as 9969.HK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for InnoCare Pharma Limited
Detailed equity research is provided by MarketSnap.